Abstract
The regulation of the cellular distribution and intracellular signaling properties of the α1B- and α1D- adrenoceptor (α1-AR) subtypes was examined in stably transfected Rat 1 fibroblasts. In unstimulated cells, α1B-AR expression was noted primarily on the cell surface. Treatment with phenylephrine induced internalization of the α1B-AR and promoted association with arrestin 2. The internalized α1B-AR colocalized with the transferrin receptor, an endosomal marker. In unstimulated fibroblasts, the α1D-AR was detected in a perinuclear orientation and was colocalized with arrestin 2 in a compartment also containing the transferrin receptor. After treatment with prazosin, which exhibits inverse agonist properties, the α1D-AR was redistributed from intracellular sites to the cellular periphery and was no longer associated with the transferrin receptor or arrestin 2. α1D-AR-expressing cells exhibited a high degree of basal activity for both inositol phosphate formation and extracellular signal regulated kinase (ERK), which was reduced by treatment with prazosin. In these cells, phenylephrine induced a dose-dependent increase in inositol phosphate formation but had no effect on ERK activity. In α1B -AR-expressing cells, phenylephrine stimulated both inositol phosphate formation and ERK activity. These data show that: 1) there are differences in the cellular localization of the α1-AR subtypes; 2) the α1B-AR exhibits expected G protein-coupled receptor activity regarding cellular localization, agonist-mediated internalization, and coupling to second messengers; and 3) the α1D-AR is constitutively active and, as a result, is localized to intracellular compartments involved in receptor recycling.
Footnotes
- Received July 28, 1999.
- Accepted December 20, 1999.
-
Send reprint requests to: Michael T. Piascik, Ph.D., Director, Vascular Biology Research Group, Dept. of Pharmacology, The University of Kentucky College of Medicine, 800 Rose St., UKMC MS 305, Lexington, KY 40536-0084. E-mail: mtp{at}pop.uky.edu
-
This work was supported by National Institutes of Health Grants HL-38120 (MTP), HL-52544 (DMP), and American Heart Association Established Investigator Award (DMP) and Scientist Development Award (GRP).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|